Latigo's mid-stage trial shows non-opioid pill LTG-001 cuts post-surgery pain, outperforms placebo

Latigo Biotherapeutics reported positive Phase 2 data for its experimental oral analgesic LTG-001, tested in patients who had undergone tummy-tuck surgery. The study enrolled 343 participants who were randomly assigned to high or low doses of the drug, a placebo, or a standard acetaminophen-hydrocodone combination.

Both dose levels of LTG-001 produced statistically significant pain reduction at the 48-hour mark compared with placebo. Moreover, patients receiving the higher dose were markedly less likely to request rescue oxycodone than those on placebo.

The safety profile appeared favorable, with the drug being well tolerated and no major adverse events reported. The results suggest LTG-001 could become a non-opioid alternative for acute postoperative pain, positioning Latigo to compete with Vertex’s existing pain therapy.